Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis.
| Publicado en: | Medical Oncology Vol. 43; no. 9; pp. 1 - 15 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Sep2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196567739&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 196567739 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 13570560 DZI jtl: Medical Oncology issn: 13570560 maglogo: N pubinfo: dt: Sep2026 vid: 43 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 196567739 10.1007/s12032-026-03343-1 196567739 ppf: 1 ppct: 14 formats: tig: atl: Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis. aug: au: Ou, Xiaoyu Li, Yan Zhan, Mengru Tao, Tiantian Chen, Pingyu affil: https://ror.org/01sfm2718 School of International Pharmaceutical Business, China Pharmaceutical University, No.639 Longmian Avenue, Jiangning District, 211198, Nanjing, Jiangsu, China sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|